Biopharmaceutical Company for Brain Health Medicine | Sage Therapeutics
Sage Therapeutics is a biopharmaceutical company developing novel therapies for brain health disorders with Depression, Neurology and Neuropsychiatric franchise programs.
About Us - Sage Therapeutics
Sage Therapeutics is a biopharmaceutical company developing novel therapies for brain health disorders with Depression, Neurology and Neuropsychiatric franchise programs.
Sage Therapeutics, Inc. (SAGE) - Yahoo Finance
Find the latest Sage Therapeutics, Inc. (SAGE) stock quote, history, news and other vital information to help you with your stock trading and investing.
Sage Therapeutics to Present 2025 Strategic Focus at 43rd …
CAMBRIDGE, Mass., January 12, 2025 -- (BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE) today announced that Chief Executive Officer Barry Greene will discuss the Company’s strategic...
Biogen Offers to Buy Remaining Stake in Sage Therapeutics
Jan 13, 2025 · Sage Therapeutics SAGE announced that its partner Biogen BIIB has made an unsolicited, non-binding proposal offer to acquire the SAGE shares that it does not already own for $7.22 per share. The ...
Sage seeks injunction after Biogen's unsolicited buyout offer
5 days ago · Sage Therapeutics has brought a lawsuit against Biogen shortly after receiving an “unsolicited” offer from its neuroscience partner. The lawsuit is sealed in Delaware’s Court of Chancery, ...
Sage to abandon development of neurological disorder drug after ...
Nov 20, 2024 · Sage Therapeutics said on Wednesday it would stop the development of its experimental drug following the latest failure in a study testing it in patients with Huntington's disease, a rare...
Our Medicines - Sage Therapeutics
Sage Therapeutics is a biopharmaceutical company developing novel therapies for brain health disorders with Depression, Neurology and Neuropsychiatric franchise programs.
Sage Therapeutics Announces U.S. Food and Drug Administration …
Oct 18, 2023 · CAMBRIDGE, Mass.-- (BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today announced the U.S. Food...
Sage Therapeutics and Biogen Announce FDA Accepts Filing of …
Feb 6, 2023 · Sage Therapeutics Safe Harbor. Various statements in this release concern Sage's future expectations, plans and prospects, including without limitation our statements regarding: the potential profile and benefit of zuranolone in the treatment of MDD and PPD; our belief that the data from our clinical programs support the potential for approval ...
- Some results have been removed